Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2010-03-11
2011-11-15
Tsang, Cecilia J (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
08058244
ABSTRACT:
Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.
REFERENCES:
patent: 6797807 (2004-09-01), Blaschuk et al.
patent: 2002/0128185 (2002-09-01), Shih
Hinds, et al. “19F n.m.r. studies of conformational changes accompanying cyclic AMP binding to 3-fluorophenylalanine-containing cyclic AMP receptor protein fromEscherichia coli,” Biochem. J. (1992), pp. 627-632.
Kubuyni, H. “Chemical Similarity and Biology Activities,” J. Braz. Chem. Soc., vol. 132, pp. 717-726, 2002.
Thronber, C.W. “Isoterism and Molecular Modification in Drug Design,” Chem. Soc. Rev. (1979) vol. 8(4), pp. 563-580.
Wormser et al. “Highly selective agonists for substance P receptor subtypes,” The EMBO Journal (1986) vol. 5, No. 11, pp. 2805-2808.
Ali, et al. “Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation,” J. Med. Chem. Mar. 18, 1994;37(6), pp. 769-780.
Suvorova, E.V. et al., Synthesis of poly(L-hydroxytryptophan), Mosk. Khim.-Tekhnol. Inst., Moskow, Russia, Zhurnal Obshchel Khimii (1993), 63(9), pp. 2126-2130, as shown in HCAPLUS in STN CAS Registry search report.
Hwang, Y. et al. “Mechanisms of inhibition of a poxvirus topoisomerase by the marine natural product sansalvamide A,” Mol. Pharmacol. Jun. 1999;55(6):1049-53.
Gu, W. “Solid-phase, Pd-catalyzed silicon-aryl carbon bond formation. Synthesis of sansalvamide A peptide,” Org. Lett. Nov. 14, 2002;4(23):4171-4174.
Lee, et al. “Rapid, High Yield, Solid-Phase Synthesis of the Antitumor Antibiotic Sansalvamide A using a Side-Chain-Tethered Phenylalanine Building Block,” Organic Letters, (2000), vol. 2, No. 23, pp. 3743-3746.
L3 Answer of 17 of 17 HCAPLUS.
Liu, S. et al. “N-Methylsansalvamide A Peptide Analogues. Potent New Antitumor Agents,” American Chemical Society, 2005, J. Med. Chem. 2005, 48, pp. 3630-3638.
Lee, Y. et al. “Silicon-based aromatic transferring linkers for traceless solid-phase synthesis of aryl-, polyaryl-, and heteroaryl-containing compounds,” Elsevier Science Ltd. 2001, Tetrahedron 57 (2001) pp. 5339-5352.
Hanford, HA. et al. “Angiostatin 4.5-mediated Apoptosis of Vascular Endothelial Cells,” Cancer Research 63, pp. 4275-4280, Jul. 15, 2003.
Fenical, W. et al. Sanslavamide: A New Cytotoxic Cyclic Depsipeptide Produced by a Marine Fungus of the GenusFusarium. Tetrahedron Letters 40, (1999) pp. 2913-2916, See p. 2913, formula 1, and p. 2915, last paragraph.
Silverman, R. et al. “Rapid, High-Yield, Solid Phase, Synthesis of the Antitumor antibiotic Sansalvamide A Using a Side-Chain-Tethered Phenylalanine Building Block,” Organic Letters 2000, vol. 2, No. 23, pp. 3743-3746. See p. 3743, paragraph 1, and formula 1.
Adrian Thomas E.
Gu Wenxin
Liu Shouxin
Silverman Richard B.
Soff Gerald A.
Heard Thomas
Northwestern University
Reinhart Boerner Van Deuren s.c.
Tsang Cecilia J
LandOfFree
Cyclic peptide antitumor agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic peptide antitumor agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic peptide antitumor agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4266569